Second , we will better integrate the patient perspective into the regulatory process . Building off of the Food and Drug Administration ' s Patient Focused Drug Development ( PFDD ) program , we are looking at ways to help strengthen FDA ' s efforts to further incorporate the patient ' s perspective . New public private partnerships that can help build the science around biomarkers and patient reported outcomes are one way to produce more collaboration , move toward faster cures and better involve patients . We also will create a predictable process for the qualification of biomarkers and patient reported outcomes so we can utilize these tools in the development process .
